Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.100
-0.025 (-0.80%)
At close: Aug 5, 2026, 4:00 PM EDT
3.030
-0.070 (-2.26%)
After-hours: Aug 5, 2026, 7:34 PM EDT

Voyager Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
36.4940.3780250.0140.9137.42
Revenue Growth
-45.50%-49.53%-68.00%511.16%9.33%-78.14%
Gross Profit
36.4940.3780250.0140.9137.42
Operating Income
-127.42-131.84-83.29122.01-50.84-73.62
Net Income
-116.64-119.72-65132.33-46.41-71.2
Earnings Per Share
-1.98-2.04-1.132.97-1.21-1.89
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
141.48196.45266.68230.88118.85132.54
Total Debt
34.5736.543.7320.2900
Net Cash (Debt)
106.91159.95222.96210.58118.85132.54
Net Cash Growth
-44.90%-28.26%5.88%77.19%-10.33%-26.83%
Net Cash Per Share
1.812.723.874.723.103.52

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-127.99-132.47-15.3177.92-12.51-53.53
Capital Expenditures
-1.95-2.6-3.52-3.26-2.49-1.61
Free Cash Flow
-129.94-135.06-18.8374.66-15-55.13
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-349.16%-326.56%-104.11%48.80%-124.28%-196.76%
Pretax Margin
-319.27%-296.17%-80.42%53.49%-113.41%-190.29%
Profit Margin
-319.61%-296.53%-81.25%52.93%-113.45%-190.29%
FCF Margin
-356.07%-334.53%-23.54%29.86%-36.67%-147.36%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
---2.84--
P/FCF Ratio
---4.98--
PS Ratio
5.135.753.881.495.762.75